References analysis of the Wikipedia article "Kanser aşısı" in the Turkish version

doi.org

Kwok M, Fritsch EF, Wu CJ (January 2021). "Cancer and COVID-19: On the Quest for Effective Vaccines". Blood Cancer Discovery. 2 (1): 13-18. doi:10.1158/2643-3230.BCD-20-0205. PMID 34661150.

Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (April 2001). "IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity". Nature. 410 (6832): 1107-1111. Bibcode:2001Natur.410.1107S. doi:10.1038/35074122. PMID 11323675.

Dunn GP, Old LJ, Schreiber RD (2004). "The three Es of cancer immunoediting". Annual Review of Immunology. 22 (i): 329-360. doi:10.1146/annurev.immunol.22.012703.104803. PMID 15032581.

Babu RA, Kumar KK, Reddy GS, Anuradha C (2010). "Cancer Vaccine : A Review". Journal of Orofacial Sciences. 2 (3): 77-82. doi:10.4103/0975-8844.103507.

Sayour EJ, Mitchell DA (6 Şubat 2017). "Manipulation of Innate and Adaptive Immunity through Cancer Vaccines". Journal of Immunology Research. 2017: 3145742. doi:10.1155/2017/3145742. PMC 5317152 $2. PMID 28265580.

Lollini PL, Cavallo F, Nanni P, Quaglino E (June 2015). "The Promise of Preventive Cancer Vaccines". Vaccines. 3 (2): 467-489. doi:10.3390/vaccines3020467. PMC 4494347 $2. PMID 26343198.

Tagliamonte M, Petrizzo A, Tornesello ML, Buonaguro FM, Buonaguro L (31 Ekim 2014). "Antigen-specific vaccines for cancer treatment". Human Vaccines & Immunotherapeutics. 10 (11): 3332-3346. doi:10.4161/21645515.2014.973317. PMC 4514024 $2. PMID 25483639.

Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L (April 2015). "Trial Watch: Peptide-based anticancer vaccines". Oncoimmunology. 4 (4): e974411. doi:10.4161/2162402X.2014.974411. PMC 4485775 $2. PMID 26137405.

"Precision medicine meets cancer vaccines". Nature Medicine. 29 (6): 1287. 16 Haziran 2023. doi:10.1038/s41591-023-02432-2. PMID 37328586.

Bafaloukos, Dimitrios (2023). "Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects". Vaccines. 11 (3): 636. doi:10.3390/vaccines11030636. PMC 10057252 $2. PMID 36992220.

Pejawar-Gaddy S, Finn OJ (August 2008). "Cancer vaccines: accomplishments and challenges". Critical Reviews in Oncology/Hematology. 67 (2): 93-102. doi:10.1016/j.critrevonc.2008.02.010. PMID 18400507.

Nishikawa M, Takemoto S, Takakura Y (April 2008). "Heat shock protein derivatives for delivery of antigens to antigen presenting cells". International Journal of Pharmaceutics. Special Issue in Honor of Prof. Tsuneji Nagai. 354 (1–2): 23-27. doi:10.1016/j.ijpharm.2007.09.030. PMID 17980980.

Savvateeva LV, Schwartz AM, Gorshkova LB, Gorokhovets NV, Makarov VA, Reddy VP, Aliev G, Zamyatnin AA (1 Ocak 2015). "Prophylactic Admission of an In Vitro Reconstructed Complexes of Human Recombinant Heat Shock Proteins and Melanoma Antigenic Peptides Activates Anti-Melanoma Responses in Mice". Current Molecular Medicine. 15 (5): 462-468. doi:10.2174/1566524015666150630125024. PMID 26122656.

Rosenberg SA, Yang JC, Restifo NP (September 2004). "Cancer immunotherapy: moving beyond current vaccines". Nature Medicine. 10 (9): 909-915. doi:10.1038/nm1100. PMC 1435696 $2. PMID 15340416.

Johnson RS, Walker AI, Ward SJ (January 2009). "Cancer vaccines: will we ever learn?". Expert Review of Anticancer Therapy. 9 (1): 67-74. doi:10.1586/14737140.9.1.67. PMID 19105708.

harvard.edu

adsabs.harvard.edu

nih.gov

ncbi.nlm.nih.gov

Kwok M, Fritsch EF, Wu CJ (January 2021). "Cancer and COVID-19: On the Quest for Effective Vaccines". Blood Cancer Discovery. 2 (1): 13-18. doi:10.1158/2643-3230.BCD-20-0205. PMID 34661150.

Dunn GP, Old LJ, Schreiber RD (2004). "The three Es of cancer immunoediting". Annual Review of Immunology. 22 (i): 329-360. doi:10.1146/annurev.immunol.22.012703.104803. PMID 15032581.

Giarelli E (October 2007). "Cancer vaccines: a new frontier in prevention and treatment". Oncology. 21 (11 Suppl Nurse Ed): 11-7; discussion 18. PMID 18154203.

Lollini PL, Cavallo F, Nanni P, Quaglino E (June 2015). "The Promise of Preventive Cancer Vaccines". Vaccines. 3 (2): 467-489. doi:10.3390/vaccines3020467. PMC 4494347 $2. PMID 26343198.

"Precision medicine meets cancer vaccines". Nature Medicine. 29 (6): 1287. 16 Haziran 2023. doi:10.1038/s41591-023-02432-2. PMID 37328586.

Rosenberg SA, Yang JC, Restifo NP (September 2004). "Cancer immunotherapy: moving beyond current vaccines". Nature Medicine. 10 (9): 909-915. doi:10.1038/nm1100. PMC 1435696 $2. PMID 15340416.

Johnson RS, Walker AI, Ward SJ (January 2009). "Cancer vaccines: will we ever learn?". Expert Review of Anticancer Therapy. 9 (1): 67-74. doi:10.1586/14737140.9.1.67. PMID 19105708.

web.archive.org

"Oral vaccine could fight source of stomach cancers". Vaccine News Reports. 24 Nisan 2015 tarihinde kaynağından arşivlendi. Erişim tarihi: 22 Haziran 2010.

Amgen press release. Amgen announces top-line results of phase 3 talimogene laherparepvec trial in melanoma. Mar 19, 2013. Available here 21 Ocak 2014 tarihinde Wayback Machine sitesinde arşivlendi.

Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. 27 Eylül 2011 tarihinde Wayback Machine sitesinde arşivlendi. S. J. Schuster, et al. 2009 ASCO Annual Meeting, J Clin Oncol 27:18s, 2009 (suppl; abstr 2)

"Approval Letter - Provenge". Food and Drug Administration. 29 Nisan 2010. 23 Temmuz 2017 tarihinde kaynağından arşivlendi. Erişim tarihi: 16 Aralık 2019.

"What Comes After Dendreon's Provenge?". 18 Ekim 2010. 14 Ağustos 2016 tarihinde kaynağından arşivlendi. Erişim tarihi: 18 Ekim 2010.

Dillow, Clay (8 Eylül 2011). "Cuba Announces Release of the World's First Lung Cancer Vaccine". Popular Science (İngilizce). 25 Ağustos 2017 tarihinde kaynağından arşivlendi. Erişim tarihi: 12 Mayıs 2023.

"Roswell Park Lung Cancer Expert Shares Initial Findings From First North American Study of CIMAvax". Roswell Park Comprehensive Cancer Center (İngilizce). 26 Eylül 2018. 12 Mayıs 2023 tarihinde kaynağından arşivlendi. Erişim tarihi: 12 Mayıs 2023.

"With Safety Analysis Now Complete, Roswell Park Moves Forward With Expanded Study of CIMAvax". Roswell Park Comprehensive Cancer Center (İngilizce). 30 Mart 2019. 12 Mayıs 2023 tarihinde kaynağından arşivlendi. Erişim tarihi: 12 Mayıs 2023.

"Immunotherapy for Bladder Cancer". Cancer Research Institute (İngilizce). 13 Ekim 2019 tarihinde kaynağından arşivlendi. Erişim tarihi: 13 Ekim 2019.

Kanser aşısı (Turkish Wikipedia)

amgen.com

asco.org

cancerresearch.org

doi.org

fda.gov

genengnews.com

harvard.edu

adsabs.harvard.edu

nih.gov

ncbi.nlm.nih.gov

popsci.com

roswellpark.org

vaccinenewsdaily.com

web.archive.org